Clinical trials: Post-COVID
Post-COVID-19 Condition, Post-COVID-19 Syndrome
Vortioxetine for Post-COVID-19 Condition
A randomized, double-blinded, placebo-controlled trial will be conducted to evaluate vortioxetine, an antidepressant with established pro-cognitive properties, for the treatment of cognitive deficits which develop during or after…
- Conditions
- Post-COVID-19 Condition, Post-COVID-19 Syndrome, Cognitive Impairment
- Trial name
- NCT05047952
- Testing
- Vortioxetine
- Where
- Canada
- Volunteers
- 149 people
- Sponsor
- Brain and Cognition Discovery Foundation
Post-COVID Postural Orthostatic Tachycardia Syndrome
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2…
- Trial name
- NCT06524739
- Testing
- IgPro20
- Where
- 38 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- CSL Behring
Long COVID, Long COVID-19
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs…
- Conditions
- Long COVID, Long COVID-19, Long COVID19
- Trial name
- NCT05965752
- Testing
- BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE
- Where
- 24 sites in United States
- Volunteers
- 328 people
- Sponsor
- Duke University